Key Investments and Partnerships
We work toward developing and delivering nutritional solutions that change the way people
approach the management of health, and that often means investing in and partnering with other
companies who have developed innovative solutions aligned with our goals.
Nestlé Health Science is an equity investor in and strategic partner of California-based Aimmune
Therapeutics (NASDAQ: AIMT), a clinical-stage biopharmaceutical company developing
proprietary product candidates and advancing a therapeutic approach for the treatment of
peanut and other food allergies.
Its Palforzia is the first and only FDA-approved oral immunotherapy for peanut allergy in patients
aged 4 through 17 years.
Aimmune’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach to treating
life-threatening food allergies is based on extensive independent scientific research
demonstrating that most patients with food allergies can become desensitized to the allergens,
or proteins, in a particular food through the oral administration of gradually increasing amounts
of the allergens. It aims to provide a transformative treatment option and allows patients to build
up protection against accidental exposures.
Nestlé Health Science will provide ongoing scientific, regulatory and commercial expertise and
advice to Aimmune.
Nestlé Health Science has made a strategic investment in Axcella (NASDAQ: AXLA), a US-
based company pioneering the research and development of novel multifactorial
interventions to support health and address dysregulated metabolism across a broad
spectrum of consumers, and patients who have limited options. AXA Candidates are
generated from Axcella’s proprietary, humanfocused AXA Development Platform and
harness the power of endogenous metabolic modulators, or EMMs, a broad family of
molecules that fundamentally impact and regulate human metabolism.
Using its AXA Development Platform, Axcella has rapidly generated a pipeline of AXA
Candidates that are novel compositions of EMMs engineered in distinct ratios and designed
to target and maximize the fundamental role that EMMs play in regulating multiple metabolic
functions. The platform has produced a rich pipeline of AXA candidates with programs in
liver, muscle, and blood among other target areas. Axcella is developing its lead AXA
Candidate, AXA1665 as a drug product for hepatic encephalopathy (HE).
Nestlé Health Science has a stake in Cerecin (previously Accera), a global healthcare company
focused on developing brain health solutions and therapeutics for patients around the world.
Cerecin's lead compound, tricaprilin, addresses the metabolic deficit that is known to be
characteristic of Alzheimer's disease by providing the brain with an alternative energy substrate.
Cerecin is currently preparing this newly reformulated compound for global pivotal studies.
For more information visit www.cerecin.com
Nestlé Health Science has formed an innovation partnership with Codexis, a pioneer in protein
engineering and enzyme optimization. The partnership will leverage and extend the application
of Codexis' CodeEvolver® protein engineering platform, creating novel enzymes that will further
fuel innovation for Nestlé Health Science's subsidiary Vitaflo, specializing in inborn errors of
metabolism, as well as for Nestlé Health Science's Consumer Care and Medical Nutrition
Nestlé Health Science has exercised its option to license Codexis' lead candidate CDX-6114, an
orally delivered enzyme designed to help better manage phenylketonuria (PKU). PKU is an
inborn and lifelong metabolic disorder that impacts the ability of patients to process protein
properly due to a malfunctioning or deficient enzyme that leads to impairment of
neurodevelopment and neurological function.
Nestlé Health Science has entered into a strategic collaboration with DBV Technologies, based
in Montrouge, France, aimed at developing and bringing to market DBV’s innovative patch-test
tool for the diagnosis of Cow’s Milk Protein Allergy (CMPA) in infants.
CMPA is a difficult to diagnose condition, which impacts up to 2-3% of infants and young
children during a critical stage of their development.
DBV’s future patch-test can become the breakthrough diagnostic for CMPA. Early diagnosis and
nutritional intervention helps get infants happily back on the path of healthy development,
alleviate the anxieties of parents, and reduce healthcare costs.
Nestlé Health Science’s reach in the field of pediatric allergy makes it an ideal commercialization
partner for DVB’s innovative diagnostic patch.
Nestlé Health Science is a strategic investor in Enterome Bioscience SA, a pioneer in the
development of novel pharmaceuticals and diagnostics to support personalized therapies in
microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic
The investment in Enterome reflects Nestlé Health Science’s intent to develop its microbiome
portfolio interests ranging from diagnosis (Dx), to therapeutics (Rx) and nutritional therapies
Enterome was established in 2012 in Paris, France, to develop the discoveries made by the
INRA metagenomic platform. The Company has attracted a range of leading venture capital
investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and strategic
investors (Nestlé Health Science, Shire & INRA transfer).
Nestlé Health Science has entered into a strategic innovation partnership with Flagship
Ventures, a leading venture capital and venture creation firm focused on innovations in
healthcare and sustainability based in Cambridge, Mass., USA. Nestlé Health Science has
invested in the Flagship Ventures Fund V. The partnership will focus on supporting start-up
ventures working on nutritional health and therapy, and is intended to provide Nestlé Health
Science with early exposure to Flagship’s innovative insights and technologies, which may be
further exploited through minority direct investments, licensing, joint ventures or acquisitions by
Nestlé Health Science. .AstraZeneca and Bayer CropScience are also strategic innovation
partners in the fund. A significant portion of the partnership’s funding is dedicated to investing in
entrepreneurial companies developing breakthrough technologies in the novel nutritional therapy
arena relevant to Nestlé Health Science, including brain, gastrointestinal and metabolic health.
Much of Flagship’s successful 15-year track record of venture funding and creation has been
built in the healthcare field, specifically in therapeutics. Through the partnership, Nestlé Health
Science gains access to Flagship’s unique model of entrepreneurial innovation through
acquisitions, minority stakes, licensing and joint-ventures. Cost effective, safe and clinically
proven nutritional therapies – that realize the potential of nutrients to impact disease and health
states at a physiological level – have a big role to play in addressing the intensifying healthcare
challenges and unmet clinical needs. This fund creates multiple opportunities that can directly
relate into the Nestlé Health Science pipeline and portfolio over time.
Nestlé Health Science has entered into a staged, milestone-based acquisition of Phagenesis, a
UK-based company developing Phagenyx®, an innovative pharyngeal electrical stimulation
device to treat dysphagia (swallowing difficulty).
Dysphagia is commonly experienced by post-stroke patients, but also older people and those
undergoing post mechanical ventilation in intensive care units. Phagenyx® is designed to
restore the neurological control of swallowing.
Advancing an integrated approach to dysphagia management, from screening, to diagnosis and
treatment, is a key goal for Nestlé Health Science and the healthcare community, ranging from
new ways to improve swallowing function to thickening agents and texture modified food to
improve swallowing safety.
Phagenyx® can bring a new dimension to swallowing rehabilitation that can be transformational from a patient and healthcare professional perspective.
In line with an intent to take a leadership position in the developing microbiome therapy field,
Nestlé Health Science has signed an exclusive agreement outside the United States and
Canada for Seres Therapeutics’ novel class of microbiome therapeutics (Ecobiotics®) in the
fields of Clostridium difficile infections (CDI, such as SER-109 and SER 262) and Inflammatory
Bowel Disease (IBD; such as SER-287 and SER-301). The agreement follows Nestlé Health
Science’s initial equity investments in US-based Seres Therapeutics announced in January and
Through this agreement, Nestlé Health Science will support the potential future
commercialization of the first ever microbiome therapy expected to be launched worldwide:
Trials are being advanced for SER 109, a candidate targeting multiple recurrent Clostridium
difficile (C. diff), a bacterial infection that can affect the digestive system. An additional C. diff
and two inflammatory bowel disease (IBD) pipeline candidates are also part of the collaboration,
including SER-287, the innovative microbiome therapeutic currently in Phase 1 clinical
development in IBD. Seres’ Ecobiotics® are first-in-field therapies, based upon microbial
organisms and target the microbiome, the 100 trillion microorganisms that live within the human
body. When unhealthy – or dysbiotic – the microbiome is increasingly understood to be causally
related to a range of diseases.
Seres Ecobiotic ® therapeutic product candidates are based upon microbial organisms,
fundamentally different from traditional drugs. Advances in genomics are progressively revealing
the importance of the microbiome, which comprise around 100 trillion microorganisms that live in
the body, to various aspects of health.